PFE Pfizer Inc

Pfizer is one of the world's largest pharmaceutical companies, known for vaccines, oncology drugs, and internal medicine, following its large Covid product cycle. Sector: Healthcare.

Pfizer Inc (PFE) is an individual stock. The analysis below presents key financial metrics for the company, covering profitability, capital efficiency, valuation, margins, and growth.

Looking at how effectively the company deploy capital, ROIC is 11.38%, WACC is 5.47%, and the economic spread is 5.91%. On balance, the spread between ROIC and WACC is narrow, leaving little buffer but still pointing to net positive value generation. Supporting metrics show ROE at 8.79% and ROA at 4.70%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a company that is value-creative but with less room for execution slippage.

From a pricing standpoint, the company sits at trailing P/E of 20.82, forward P/E of 9.57. A wide spread between trailing and forward P/E implies the market is embedding substantial earnings improvement into current prices. A current ratio reading of 1.16 suggests the company carries less short-term financial cushion than the broader market average. In total, the multiple and liquidity readings describe a company where valuation is a secondary risk relative to earnings delivery — the numbers are defensible if estimates hold.

Across the three margin layers, gross margin sits at 75.07%, operating margin at 29.22%, and free cash flow margin at 14.50%. The gross margin reading is exceptional — a reliable indicator of competitively advantaged businesses. Operating margins are in good shape, consistent with businesses that maintain reasonable earnings conversion after overhead. At this level, free cash flow generation is present but not a defining strength of the company's underlying businesses. This margin configuration supports a cautious interpretation: profitability exists, though durability is less certain under stress.

Two key indicators frame the near-term view: TTM revenue growth of -1.65% a signal that top-line momentum has stalled or reversed at the company level, while the estimated 12-month price change of 3.93%, where implied appreciation is modest based on current target assumptions. The near-term return case is built on whether reported trends and analyst projections can remain close enough to make current prices look justified. Whether the setup resolves positively or negatively will depend as much on the macro backdrop as on the capacity of the company to deliver against current estimates. The estimated 12-month price change is based on analyst consensus price target estimates, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

Balancing the strengths against the areas of uncertainty, the weight of evidence favors an optimistic view with appropriate risk awareness.

This summary is based on publicly available quantitative data and is not intended as investment advice. Carefully consider your personal financial circumstances before making any decisions.